H101 Combined With Camrelizumab for Recurrent Cervical Cancer

Clinical trial NCT05234905 · UNKNOWN

Trial details

NCT number: NCT05234905
Sponsor: Zhejiang Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Uterine Cervical Neoplasms Oncolytic Virotherapy Camrelizumab

Start date: 2022-03-01
Primary completion: 2023-06-01
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.